Real-World data on firmonertinib for lung cancer that spread to the brain
NCT ID NCT07239102
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked back at medical records of 300 people with EGFR-positive non-small cell lung cancer that had spread to the brain or spinal cord. All patients were treated with the drug firmonertinib. Researchers analyzed how long the drug controlled brain tumors and explored why some patients stopped responding. The goal is to better understand real-world effectiveness and resistance patterns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Firmonertinib (oral drug)
What this could lead to
If successful, this analysis could help identify which patients benefit most from firmonertinib and how resistance develops, guiding future treatment strategies.
What could go wrong
This is a retrospective review of past medical records, not a controlled trial. Results may be influenced by incomplete data or patient selection bias.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Li Xiaoyan
Beijing, Beijing Municipality, China